A deadly outbreak of Andes virus has been linked to the MV Hondius cruise ship, highlighting a critical gap in medical preparedness. Three people on board tested positive for hantavirus, including one passenger who died. Five more suspected infections have been reported, with two additional deaths.
The culprit, Andes virus, is a rare hantavirus species capable of person-to-person transmission, unlike most rodent-borne hantaviruses. Scientists suspect some travelers may have been infected in Argentina before boarding.
Currently, no licensed vaccine or specific treatment exists for Andes virus. While hantavirus infections are rare, some species carry a fatality rate of up to 50%, making prevention and early recognition critical.
For over three decades, researchers have pursued a vaccine, with strong interest from the military. A key advance includes a hamster model that replicates hantavirus pulmonary syndrome. Phase I trials for a DNA vaccine have shown it induces neutralizing antibodies, but it requires at least three doses. The rarity of cases makes standard Phase III efficacy trials extremely difficult, leading to a search for alternative licensing pathways. Funding remains a major barrier.
For physicians, this outbreak underscores the importance of considering hantavirus in patients with compatible symptoms and travel history, especially to areas with reservoir rodents. Until a vaccine or therapy is licensed, clinical readiness depends on rapid diagnosis, supportive care, and heightened public health surveillance.